Immunovant Quarterly Balance Sheet
NASDAQ: IMVTHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Immunovant financial position
As of Jun 30, 2026, Immunovant reported total assets of $852.5 million, up 28.9% from a year earlier against total liabilities of $117.1 million. Shareholders' equity stood at $735.4 million, or 86.3% of assets. The company held $797.8 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 7.27, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Immunovant balance sheet (quarterly)
| Quarter (USD) | Q1 20272026-06-30 | Q4 20262026-03-31 | Q3 20262025-12-31 | Q2 20262025-09-30 | Q1 20262025-06-30 | Q4 20252025-03-31 | Q3 20252024-12-31 | Q2 20252024-09-30 | Q1 20252024-06-30 | Q4 20242024-03-31 | Q3 20242023-12-31 | Q2 20242023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 797.80M | 902.11M | 994.52M | 521.87M | 598.91M | 713.97M | 374.69M | 472.94M | 560.00M | 635.37M | 690.94M | 269.93M |
| Receivables | 697.00K | 1.13M | 1.64M | 1.97M | 1.94M | 2.08M | 2.22M | 1.88M | 2.42M | 5.34M | 1.03M | 1.42M |
| Total Current Assets | 851.18M | 948.82M | 1.04B | 573.55M | 651.76M | 767.66M | 412.54M | 507.37M | 589.05M | 665.77M | 710.78M | 291.18M |
| Property, Plant & Equipment | 351.00K | 443.00K | 531.00K | 632.00K | 737.00K | 844.00K | 752.00K | 671.00K | 565.00K | 462.00K | 376.00K | 304.00K |
| Total Assets | 852.49M | 957.01M | 1.05B | 582.96M | 661.44M | 776.22M | 420.93M | 515.71M | 589.68M | 666.37M | 711.45M | 292.07M |
| Accounts Payable | 10.14M | 7.54M | 8.62M | 6.92M | 7.84M | 17.66M | 19.82M | 20.73M | 11.04M | 7.16M | 3.91M | 7.51M |
| Total Current Liabilities | 117.10M | 104.42M | 66.26M | 63.25M | 52.90M | 68.78M | 68.31M | 66.65M | 45.02M | 48.61M | 32.10M | 40.26M |
| Total Liabilities | 117.10M | 104.42M | 66.26M | 63.25M | 52.90M | 68.78M | 68.31M | 66.65M | 45.02M | 48.61M | 32.10M | 40.26M |
| Shareholders' Equity | 735.39M | 852.59M | 986.13M | 519.71M | 608.54M | 707.45M | 352.62M | 449.05M | 544.66M | 617.76M | 679.34M | 251.81M |
| Retained Earnings | -1.90B | -1.75B | -1.60B | -1.49B | -1.36B | -1.24B | -1.13B | -1.02B | -912.83M | -825.68M | -750.36M | -698.95M |
| Net Cash (Debt) | 797.80M | 902.11M | 994.52M | 521.87M | 598.91M | 713.97M | 374.69M | 472.94M | 560.00M | 635.37M | 690.94M | 269.93M |
| Shares Outstanding | 206.26M | 203.94M | 203.32M | 174.53M | 171.07M | 170.11M | 147.20M | 146.57M | 146.20M | 145.58M | 145.09M | 131.44M |
This table shows 12 quarterly periods of Immunovant's balance sheet, from Q1 2027 back to Q2 2024, across 13 line items including cash & equivalents, receivables, total current assets. Values in USD; B = billions, M = millions. Fiscal periods follow IMVT's reporting calendar. What is a balance sheet?